Profit margins

Profit margins of NovoSorb sales at the moment right off the bat are over 90%.

 

And that is taking into account the fact that NovoSorb is selling for around half the price of its main competitors whose products, being biological based products are much more expensive to produce. There is no way they can compete against this.

 

So we have a product that is superior in almost every way - more easily stored, easier to use, less prone to infection, incredibly cheap to produce, better results.

 

We are literally selling a special biodegradable piece of plastic. It's as close to printing money as you can get.

 

I cannot think of another biotech that has gross profit margins anywhere near this. When PNV gets scale this the profit margins are going to get as close to 99% as you'll ever see in this industry.

 

These margins will make the runway to breakeven very very quick.

 

I am expecting this to be a billion dollar company in the next few months. It may be bumpy, but it will get there soon enough.

 

When PNV gets more coverage from analysts and added to the ASX200, it is going to go ballistic as everyone starts finding out more about this company.

 

As a retail investor this is one of the few edges we have - we can look at stocks and not be restricted by market cap size or other restrictions on investment mandates.

 

Enjoy the opportunity while it lasts, it won't be long before PNV hits the big league.